Sera Prognostics, Inc. ( (SERA) ) has released its Q4 earnings. Here is a breakdown of the information Sera Prognostics, Inc. presented to its investors.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Sera Prognostics, Inc., a health diagnostics company based in Salt Lake City, Utah, is dedicated to improving maternal and neonatal health through precision pregnancy care, notably offering the PreTRM Test for early prediction of preterm birth risk.
In its latest earnings report for the fourth quarter and full year 2024, Sera Prognostics highlighted significant developments, including the successful results of its PRIME study and a substantial capital raise to support future growth.
Key financial metrics revealed a decrease in revenue to $24,000 for the fourth quarter of 2024, down from $41,000 in the same period of 2023, with a net loss of $8.6 million. However, operating expenses were managed effectively, with a slight increase to $9.4 million, reflecting strategic investments in product development and commercialization. For the full year, revenue fell to $77,000 from $306,000 in 2023, while net loss decreased to $32.9 million from $36.2 million, aided by reduced operating expenses.
Strategically, Sera Prognostics plans to leverage the $57.5 million raised in a public offering to expand its commercial efforts in the U.S. and Europe, and to fund additional studies for its PreTRM test, potentially seeking FDA approval.
Looking ahead, Sera Prognostics remains focused on advancing its mission to reduce the societal and healthcare costs associated with premature birth, supported by its recent financial and strategic initiatives.